<DOC>
	<DOCNO>NCT02138331</DOCNO>
	<brief_summary>Type 1 diabetes mellitus strictly autoimmune mediate disease destruct islet β-cell pancreas . Mesenchymal stem cell microvesicles report anti-inflammatory agent . We hypothesis intravenous infusion cell free umbilical cord-blood derive MSC microvesicles may reduce inflammatory state hence improve β-cell mass well glycemic control patient T1DM .</brief_summary>
	<brief_title>Effect Microvesicles Exosomes Therapy β-cell Mass Type I Diabetes Mellitus ( T1DM )</brief_title>
	<detailed_description>- Twenty T1DM patient , age 18-60 year reduction C-peptide chain 50 % , C-peptide 0.8 ng/mL Screening require insulin ≥0.4 IU per kg per day . - Twenty T1DM patient entry selection criterion subject step except microvesicles administration control group . - Study follow period : Three month - Gender : Both male female include - Entry selection criterion include : UACR le 300 , BUN 10-20 mg/dl , serum creatinin 0.6-1.4 mg/dl normal liver enzymes , normal serum bilirubin , normal serum albumin coagulation profile ) . C-peptide 0.8 ng/mL Screening . BMI 20-40 kgm/m2 - Exclusion criterion : Other autoimmune disease . Pregnancy . Previous treatment stem cell . All patient control investigated HBV , HCV &amp; HIV PCR test enrollment study positivity parameter mean exclusion patient study . - The primary end point end three month follow . At day ( 0 ) : All patient control subject follow investigation : Liver function test , kidney function test , HbA1c , glucose tolerance test ( GTT ) , fast 2 hrs.post prandial blood glucose level , C-peptide chain level calculate total daily insulin dose . After three month ( end study ) investigation repeat . Two intravenous infusion cell free cord-blood derive mesenchymal stem cell [ CB-MSC ] microvesicles : - The first dose purify exosomes , range 40-180 nm , dose supernatant produce ( 1.22-1.51 ) × 10 ( 6 ) /kg/IV . ( Characterization exosomes : CD63 , CD9 , Alix , TSG 101 , HSP 70 ) . - The second dose , 7 day , microvesicles , range 180-1000 nm , dose supernatant produce ( 1.22-1.51 ) × 10 ( 6 ) /kg/IV . ( Characterization microvesicles : ( Annexin V , Flotillin-2 , selectin , integrin , CD40 metalloproteinase ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>UACR le 300 , BUN 1020 mg/dl , serum creatinin 0.61.4 mg/dl normal liver enzymes , normal serum bilirubin , normal serum albumin coagulation profile ) . Cpeptide 0.8 ng/mL Screening . BMI 2040 kgm/m2 . Other autoimmune disease . Pregnancy . Previous treatment stem cell . All patient control investigated HBV , HCV &amp; HIV PCR test enrollment study positivity parameter mean exclusion patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Diabetes Mellitus Type 1</keyword>
	<keyword>Microvesicles</keyword>
	<keyword>Exosomes</keyword>
	<keyword>Cord Blood</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
</DOC>